Suppr超能文献

干酪乳杆菌YIT 9018(LC 9018)的抗肿瘤活性——给药途径的影响

[Antitumor activity of Lactobacillus casei YIT 9018 (LC 9018)--effect of administration route].

作者信息

Yokokura T, Kato I, Matsuzaki T, Mutai M, Satoh H

出版信息

Gan To Kagaku Ryoho. 1984 Nov;11(11):2427-33.

PMID:6437346
Abstract

Antitumor activity of lactobacilli on Sarcoma 180 was investigated and was shown to be different from strain to strain. In general, Lactobacillus casei had higher antitumor activity compared with other species of lactobacilli. Among these, L. casei YIT 9018 (LC 9018) had significant antitumor activity against Meth A fibrosarcoma when administered into BALB/c mice intravenously, intraperitoneally, subcutaneously, intratumorally or orally. LC 9018 showed antitumor activity against rat ascites hepatoma by intravenous or oral administration, but this activity was lower than that against Meth A in mice.

摘要

研究了乳酸杆菌对肉瘤180的抗肿瘤活性,结果表明不同菌株的活性有所不同。一般来说,与其他乳酸杆菌种类相比,干酪乳杆菌具有更高的抗肿瘤活性。其中,干酪乳杆菌YIT 9018(LC 9018)经静脉、腹腔、皮下、瘤内或口服给药至BALB/c小鼠后,对Meth A纤维肉瘤具有显著的抗肿瘤活性。LC 9018经静脉或口服给药对大鼠腹水肝癌显示出抗肿瘤活性,但该活性低于对小鼠Meth A的活性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验